Erchonia XLR8 Laser Granted FDA Clearance for Pain Treatment

Press Releases concerning clinical trial results are intended to inform interested parties of the advancements of laser technology in process, not to imply new indications for use. Erchonia supports only those indications for use, cleared by the FDA via 510(k).

Contact: Katie Cycan
Crier Communications
310-274-1072 x 207
katie@crierpr.com
 

Erchonia XLR8 Laser Granted FDA Clearance for Pain Treatment

McKinney, TX – October 21, 2013 – Erchonia, the global leader in low level laser healthcare applications, today announces the company has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) to market its new XLR8 Laser for pain treatment.
Depending on the settings selected, the Erchonia XLR8 laser can provide temporary relief of minor chronic neck and shoulder pain; reduce pain after liposuction of the thighs, hips and stomach; or reduce post-surgery pain after breast augmentation.
The Erchonia XLR8 laser is a handheld device that uses low level laser technology to speed the recovery process by encouraging cell regeneration. The XLR8 laser is a noninvasive, safe way to manage pain—without negative side effects.
Steven Shanks, president of Erchonia comments, “The Erchonia XLR8 laser combines three FDA 510(k) market clearances into one device. With user-definable channels, an easy-to-use interface, and preset protocols, cold laser technology is now more flexible than ever before.”
For more information on the Erchonia XLR8 laser, please visit www.erchonia.com.
 
About Erchonia
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit www.erchonia.com.